Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
|Articles|August 25, 2022
Daily OTC Pearl: Protazen
Author(s)Saro Arakelians, PharmD
Protazen is intended to help with mental and mood enhancement.
Advertisement
OTC/Lifestyle Pearl of the Day: Protazen
Indication: Protazen is intended to help with mental and mood enhancement.
Insight:
- Product contains thiamine.
- Take as directed on the bottle.
- Do not take with other regular medications.
- Keep at room temperature.
- Keep away from children.
Source:
Advertisement
Related to this article
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5